ReviewMayo Clinic proceedings2011
Current concepts in antifungal pharmacology.
Review in Mayo Clinic proceedings, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 125 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
125 citing papers in PubMed, 362 citations in OpenAlex.
- A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Research trends and emerging topics in antifungal therapeutic drug monitoring: a bibliometric analysis with implications for clinical pharmacy practice.International journal of clinical pharmacy · 2026Review
- Pterostilbene-Incorporated Tissue Conditioners Exhibit Sustained Antifungal Activity AgainstMaterials (Basel, Switzerland) · 2026Article
- Candida Infections in Marine Mammals: Epidemiology, Antifungal Resistance, and One Health Implications.Animals : an open access journal from MDPI · 2026Review
- Article
- Iturin A disruptsNpj fungal science · 2026Article
- Diagnosis and management of invasive candidiasis in critically ill patients: SIAARTI multidisciplinary statement.Journal of anesthesia, analgesia and critical care · 2025Review
- Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective.Journal of clinical medicine · 2025Review
- Antifungal Agents in the 21st Century: Advances, Challenges, and Future Perspectives.Infectious disease reports · 2025Review
- Single-Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs.Journal of veterinary pharmacology and therapeutics · 2025Article
- Harnessing Non-Antibiotic Strategies to Counter Multidrug-Resistant Clinical Pathogens with Special Reference to Antimicrobial Peptides and Their Coatings.Antibiotics (Basel, Switzerland) · 2025Review
- Recent innovations and challenges in the treatment of fungal infections.Frontiers in cellular and infection microbiology · 2025Review
- Predictors of caspofungin exposure-response relationship: a retrospective cohort study on therapeutic drug monitoring parameters.Frontiers in pharmacology · 2025Article
- Metabolic Biomarkers of Liver Failure in Cell Models and Patient Sera: Toward Liver Damage Evaluation In Vitro.International journal of molecular sciences · 2024Article
- Vitamin B5 metabolism is essential for vacuolar and mitochondrial functions and drug detoxification in fungi.Communications biology · 2024Article
- Development and Quality Control of a Population Pharmacokinetic Model Library for Caspofungin.Pharmaceutics · 2024Article
- Exploring the frontiers of therapeutic breadth of antifungal peptides: A new avenue in antifungal drugs.Journal of industrial microbiology & biotechnology · 2024Review
- Navigating the fungal battlefield: cysteine-rich antifungal proteins and peptides from Eurotiales.Frontiers in fungal biology · 2024Review
- Antifungal resistance: why are we losing this battle?Future microbiology · 2024Review
- Dose Optimization of Fluconazole After Initial Treatment Failure in Pulmonary Cryptococcosis in an Obese Patient with Type 2 Diabetes and Cirrhosis: A Case Report.Infection and drug resistance · 2024Article
65 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of new antifungal agents (eg, echinocandins, second-generation triazoles) in the past decade has transformed the management of invasive mycoses to the point that drug toxicity is no longer the major limiting factor in treatment. Yet, many of these newer antifungal agents have important limitations in their spectrum of activity, pharmacokinetics, and unique predisposition for pharmacokinetic drug-drug interactions and unusual toxicities associated with long-term use. This article reviews key pharmacological aspects of systemic antifungal agents as well as evolving strategies, such as pharmacokinetic-pharmacodynamic optimization and therapeutic drug monitoring, to improve the safety and efficacy of systemic antifungal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.